An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, inAdvanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations- J5M-OX-JOXA

Contact:

NCT Number:

Protocol:

AAAV3545

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I

The purpose of this study is to test the safety of an investigational treatment called LY4050784 in subjects with solid tumors that have a particular genetic abnormality (called an alteration or mutation) of a gene called SMARCA4 and/or BRG1. LY4050784 is an investigational (or experimental) drug, taken by mouth that targets a gene called SMARCA2/BRM, and may treat certain cancers. Investigational means neither the FDA nor any other health or regulatory authority in other countries have approved LY4050784. This study will be the first time LY4050784 will be tested in humans.

Are you Eligible? (Inclusion Criteria)

  • You are ≥ 18 years of age 2. You are able to swallow capsules/tablets. 3. You have locally advanced or metastatic solid tumor malignancy (except central nervous system [CNS] primary malignancy) with BRG1/SMARCA4 alteration

Specialty Area(s)

Bladder Cancer , Breast Cancer, Colon and Rectal Cancer, Esophageal Cancer, Kidney Cancer/Adrenal Cancer, Liver Cancer, Lung cancer, Skin cancers, Pancreatic Cancer, Prostate Cancer, Stomach Cancer, Thyroid Cancer

Principal Investigator

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032